drugset / Trial / NCT01941849
Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma
NaSingle-groupOpen-labelTreatment
Summary
The phase I trial aims to determine the recommended phase II dose (RP2D) of vandetanib in combination with standard radiation therapy, 131I-mIBG, in patients with advanced phaeochromocytoma (phaeo) and paraganglioma (PG) by assessing the safety and tolerability of the combination treatment.
Timeline
- Start
- 2014-10
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vandetanib | Small molecule | 100 mg | — |
| Subject | Vandetanib | Small molecule | 200 mg | — |
| Subject | Vandetanib | Small molecule | 300 mg | — |